Payment overview · 2025
General Payments
$1,051.94
12 reported records · 9 companies
Healthcare provider profile · identity verified
Sunil Arora, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Sleep Medicine · SAN BERNARDINO, CA · NPI 1962583104
Verified facts
What the public records show
CMS Open Payments records show Sunil Arora, MD received $1,051.94 in general payments during 2025 across 12 reported records.
Cook Incorporated accounted for 35.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ofev by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Cook Incorporated | Unresolved — no canonical attribution shown | $369.54 | 35.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $250.61 | 23.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $128.63 | 12.2% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $99.95 | 9.5% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $61.00 | 5.8% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $40.51 | 3.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.00 | 3.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.00 | 3.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $25.70 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $536.53 | 8 |
| Travel and Lodging | $369.54 | 1 |
| Education | $145.87 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BLUE RHINO Normalized: blue rhino |
Device | Cook Incorporated | $369.54 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $128.63 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $99.95 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $99.95 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $61.00 | 1 | 2025 |
Source payment records
|
|||||
| Respiratory Normalized: respiratory |
Device | Philips North America LLC | $40.51 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $40.00 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $36.00 | 1 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $25.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
47 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
116 | 27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
92 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 1172 | 353 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 899 | 196 |
| Atorvastatin Calcium | Atorvastatin Calcium | 390 | 98 |
| Fluticasone Propionate | Fluticasone Propionate | 307 | 92 |
| Ozempic | Semaglutide | 293 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 273 | 70 |
| Furosemide | Furosemide | 238 | 82 |
| Gabapentin | Gabapentin | 211 | 52 |
| Lisinopril | Lisinopril | 199 | 51 |
| Metformin Hcl | Metformin Hcl | 199 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 168 | 48 |
| Omeprazole | Omeprazole | 166 | 49 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 159 | 113 |
| Alendronate Sodium | Alendronate Sodium | 151 | 35 |
| Potassium Chloride | Potassium Chloride | 149 | 54 |
| Serevent Diskus | Salmeterol Xinafoate | 142 | 34 |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 140 | 45 |
| Eliquis | Apixaban | 117 | 25 |
| Jardiance | Empagliflozin | 116 | 27 |
| Montelukast Sodium | Montelukast Sodium | 110 | 34 |
| Benazepril Hcl | Benazepril Hcl | 101 | 26 |
| Losartan Potassium | Losartan Potassium | 100 | 29 |
| Trazodone Hcl | Trazodone Hcl | 100 | 27 |
| Entresto | Sacubitril/Valsartan | 99 | 16 |
| Ofev | Nintedanib Esylate | 92 | 12 |
| Levothyroxine Sodium | Levothyroxine Sodium | 91 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 36 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 83 | 28 |
| Carvedilol | Carvedilol | 80 | 23 |
| Simvastatin | Simvastatin | 80 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 21 |
| Qvar Redihaler | Beclomethasone Dipropionate | 75 | 25 |
| Famotidine | Famotidine | 74 | 19 |
| Januvia | Sitagliptin Phosphate | 71 | 17 |
| Spiriva Respimat | Tiotropium Bromide | 69 | 15 |
| Azithromycin | Azithromycin | 65 | 36 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 62 | 18 |
| Atrovent Hfa | Ipratropium Bromide | 62 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 62 | 34 |
| Baclofen | Baclofen | 61 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 61 | 21 |
| Prednisone | Prednisone | 58 | 31 |
| Breyna | Budesonide/Formoterol Fumarate | 55 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 54 | 18 |
| Ezetimibe | Ezetimibe | 53 | 13 |
| Aralast Np | Alpha-1-Proteinase Inhibitor | 51 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 51 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 51 | 20 |
| Symbicort | Budesonide/Formoterol Fumarate | 47 | 16 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 45 | 14 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 44 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 40 | suppressed |
| Allopurinol | Allopurinol | 39 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 38 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 36 | suppressed |
| Xolair | Omalizumab | 36 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | 12 |
| Lidocaine | Lidocaine | 35 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 35 | 13 |
| Steglatro | Ertugliflozin Pidolate | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 15 |
| Repatha Sureclick | Evolocumab | 28 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 26 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 26 | 15 |
| Gemtesa | Vibegron | 25 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 25 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 18 |
| Spironolactone | Spironolactone | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Roflumilast | Roflumilast | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Nucala | Mepolizumab | 18 | suppressed |
| Prolia | Denosumab | 18 | suppressed |
| Dupixent Syringe | Dupilumab | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Alogliptin | Alogliptin Benzoate | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Isoniazid | Isoniazid | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,051.94 · 12 records | Cook Incorporated | BLUE RHINO, BREZTRI, DUPIXENT, JASCAYD, Kerendia, OPSUMIT, REPATHA, Respiratory, UPTRAVI, ZERBAXA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error